CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 136 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 12.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $22 | +1000.0% | 18,481 | +1417.3% | 0.00% | – |
| Q1 2024 | $2 | +100.0% | 1,218 | -2.6% | 0.00% | – |
| Q4 2023 | $1 | -100.0% | 1,251 | -91.8% | 0.00% | – |
| Q2 2022 | $27,000 | -32.5% | 15,186 | 0.0% | 0.00% | – |
| Q1 2022 | $40,000 | -25.9% | 15,186 | +83.1% | 0.00% | – |
| Q4 2020 | $54,000 | +575.0% | 8,292 | +761.1% | 0.00% | – |
| Q2 2020 | $8,000 | -97.9% | 963 | -98.1% | 0.00% | -100.0% |
| Q1 2020 | $380,000 | -7.8% | 49,600 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $412,000 | +9.3% | 49,600 | -3.1% | 0.00% | 0.0% |
| Q3 2019 | $377,000 | -34.3% | 51,200 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $574,000 | +4.4% | 51,200 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $550,000 | -6.9% | 51,200 | +30.6% | 0.00% | 0.0% |
| Q4 2018 | $591,000 | -18.5% | 39,200 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $725,000 | – | 39,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Canaan Partners IX LLC | 4,244,381 | $43,378,000 | 100.00% |
| VHCP Management II, LLC | 577,831 | $5,905,000 | 3.56% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 71,366 | $729,000 | 2.45% |
| Casdin Capital, LLC | 234,179 | $2,392,000 | 2.38% |
| BVF INC/IL | 606,138 | $6,192,000 | 1.32% |
| Opaleye Management Inc. | 160,000 | $1,634,000 | 1.09% |
| Redmile Group, LLC | 733,899 | $7,497,000 | 0.72% |
| VHCP Management, LLC | 64,200 | $656,000 | 0.68% |
| Montecito Bank & Trust | 146,544 | $1,497,000 | 0.63% |
| Cormorant Asset Management, LP | 371,636 | $3,796,000 | 0.54% |